Skip to search formSkip to main contentSkip to account menu

Milligram per Square Meter per Week

Known as: Milligram/meter2/week, mg/m2/week, mg/m2/wk 
A dose calculation unit expressed in milligram(s) per square meter per period of time equal to seven days.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Biweekly liposomal pegylated doxorubicin in elderly women with advanced breast cancer: A prospective multicenter trial focusing on tolerability and cardiotoxicity.
1138 Background: To assess tolerability and activity of liposomal pegylated doxorubicin (PLD) in women older than 70 years with… 
2010
2010
Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial.
5534 Background: Cetuximab combined with RT is a treatment option for locally advanced head and neck cancer, especially for… 
2010
2010
Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard…
1073 Background: Two phase IIb trials in pts with advanced BC demonstrated activity for SOR plus standard chemotherapy for the… 
2002
2002
A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane.
PURPOSE We performed a phase II trial to evaluate the efficacy and the safety of gemcitabine monotherapy, a pyrimidine… 
1993
1993
The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose‐intense taxol and granulocyte colony stimulating factor
Forty-eight patients with recurrent adenocarcinoma of the ovary were treated with taxol and granulocyte colony stimulating factor… 
1982
1982
Vindesine in bronchogenic carcinoma: a phase II trial.
Twenty-seven patients with advanced bronchogenic carcinoma were treated with vindesine, 3 mg/m2/week. Twenty-three patients were… 
1982
1982
Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
9,10-Anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-y1)-hydrazone ]dihydrochloride (bisantrene) is one of a series of… 
1981
1981
Phase I study on bruceantin administered on a weekly schedule.
Fifteen adult patients with advanced solid tumors received bruceantin at doses of 1.6-6.0 mg/m2 iv for 30 minutes/week X 4… 
1980
1980
Phase I trial of PALA.
PALA was given iv on a weekly schedule to 32 patients with advanced malignant tumors. A course of treatment consisted of three… 
1979
1979
Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
VM-26, a semisynthetic podophyllotoxin, was tested for antitumor activity and clinical toxicity in 181 children. The drug was…